Second Alzheimer’s drug, donanemab, succeeds in Phase 3 trial

WFAC image

By Nicola Williams | Wednesday 03 May 2023

Today, the pharmaceutical company Eli Lilly announced that their Alzheimer’s drug, donanemab, has successfully slowed memory and thinking decline in a rigorous phase 3 trial. The TRAILBLAZER ALZ-2 trial tested the drug in nearly 1,200 people with early-stage Alzheimer’s disease.

The announcement makes this the second drug to show positive results in the last six months.

What does this mean for dementia research?

According to Lilly’s press release, the trial showed that participants who took donanemab had a slower rate of decline in memory and thinking skills, compared to people who did not receive the drug.

“We’re now on the cusp of a first generation of treatments for people with Alzheimer’s disease.” – Dr Susan Kohlhaas

“This is incredibly encouraging, and another hugely significant moment for dementia research,” commented Dr. Susan Kohlhaas, Executive Director of Research & Partnerships at Alzheimer’s Research UK.

“A second drug for Alzheimer’s has been shown to slow people’s cognitive decline in a rigorous phase 3 trial. We’re now on the cusp of a first generation of treatments for Alzheimer’s disease, something that many thought impossible only a decade ago.”

What happens now?

Dr Susan Kohlhaas, Executive Director of Research & Partnerships

As with other drugs that have emerged recently, donanemab works by removing build-up of a protein called amyloid – a hallmark of Alzheimer’s – from the brain.

The treatment effect of donanemab is modest, and some participants in the trial have experienced significant side effects from the drug. These need to be “fully scrutinized” before it can be marketed and used. Dr Kohlhaas also highlighted “the urgency of preparing the NHS to make these treatments available should regulators deem them safe and effective.”

Nevertheless, this is a significant step forward in the quest for new Alzheimer’s treatments.

“People should be really encouraged by this news, which is yet more proof that research can take us ever closer towards a cure.”

 

By submitting a comment you agree to our comments policy.
Please do not post any personal information about yourself or anyone else, especially any health data or other sensitive data. If you do submit sensitive data, you consent to us handling it in line with our comments policy.

1 Comment

  1. Richard Marsters on 4th April 2024 at 7:14 pm

    This is good news to me.
    Both my grandparents on my father’s side, my father and his three elder siblings had before passing away or are currently living with alzheimers.
    I am 52 and don’t believe I show any signs of Alzheimer’s but it is comforting to know that some progress is being made.

Leave a Comment





About the author

Nicola Williams